CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 106,881 enrolled
Drug / intervention
Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay +5 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03285295
NCT03285295N/ACompleted

Abbott Laboratories Alinity s Blood Screening Assays - Clinical Evaluation Protocol

Abbott Diagnostics Division·interventional·Posted Sep 18, 2017·Updated Oct 9, 2019

In Brief

A clinical study evaluating Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay, Alinity s HTLV I/II Assay, and 4 other interventions for Healthy. Completed, enrolled 106,881 participants across 5 sites.

Detailed Summary

The objective of this study is to demonstrate the performance and intended use of each of the Alinity s investigational assays in a donor screening environment using clinical specimens to evaluate assay performance characteristics. A comparison of assay performance will be done versus the Food and Drug Administration (FDA) licensed assays. The data will be used to support regulatory submissions and/or publications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedSep 18, 2017
Enrollment StartSep 15, 2017
Primary CompletionMay 23, 2018
Study CompletionJun 21, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.8 years ago

Interventions

Alinity s HBsAg and Alinity s HBsAg Confirmatory Assaydevice

For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Alinity s HTLV I/II Assaydevice

For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Alinity s Anti-HCV Assaydevice

For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Alinity s HIV Ag/Ab Combo Assaydevice

For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Alinity s Anti-HBc Assaydevice

For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Alinity s Chagas Assaydevice

For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.